| Janelle Mcgill, MD | |
|
1120 15th St, Augusta, GA 30912-0004 | |
| (706) 721-8623 | |
| Not Available |
| Full Name | Janelle Mcgill |
|---|---|
| Gender | Female |
| Speciality | Pediatric Medicine |
| Experience | 9 Years |
| Location | 1120 15th St, Augusta, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003299793 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 7483 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Au Medical Associates Inc | 9931013513 | 577 |
News Archive
Among patients who have suffered a single stroke, researchers at the University of Pennsylvania School of Medicine, along with colleagues at other institutions, have found that severe stenosis, or narrowing, of the arteries in the head represents a major risk factor for the development of a subsequent stroke.
Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
Abnormalities in glucose uptake by the liver (or hepatic glucose uptake; HGU) cause elevations in blood glucose levels following meals, a state that is known as postprandial hyperglycemia.
› Verified 9 days ago
| Entity Name | Au Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841230620 PECOS PAC ID: 9931013513 Enrollment ID: O20040107000188 |
News Archive
Among patients who have suffered a single stroke, researchers at the University of Pennsylvania School of Medicine, along with colleagues at other institutions, have found that severe stenosis, or narrowing, of the arteries in the head represents a major risk factor for the development of a subsequent stroke.
Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
Abnormalities in glucose uptake by the liver (or hepatic glucose uptake; HGU) cause elevations in blood glucose levels following meals, a state that is known as postprandial hyperglycemia.
› Verified 9 days ago
| Entity Name | Wellstar Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558664003 PECOS PAC ID: 6709065402 Enrollment ID: O20110127000374 |
News Archive
Among patients who have suffered a single stroke, researchers at the University of Pennsylvania School of Medicine, along with colleagues at other institutions, have found that severe stenosis, or narrowing, of the arteries in the head represents a major risk factor for the development of a subsequent stroke.
Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
Abnormalities in glucose uptake by the liver (or hepatic glucose uptake; HGU) cause elevations in blood glucose levels following meals, a state that is known as postprandial hyperglycemia.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Janelle Mcgill, MD 1120 15th St, Augusta, GA 30912-0004 Ph: () - | Janelle Mcgill, MD 1120 15th St, Augusta, GA 30912-0004 Ph: (706) 721-8623 |
News Archive
Among patients who have suffered a single stroke, researchers at the University of Pennsylvania School of Medicine, along with colleagues at other institutions, have found that severe stenosis, or narrowing, of the arteries in the head represents a major risk factor for the development of a subsequent stroke.
Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.
FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.
Abnormalities in glucose uptake by the liver (or hepatic glucose uptake; HGU) cause elevations in blood glucose levels following meals, a state that is known as postprandial hyperglycemia.
› Verified 9 days ago
Kenny Esho, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1120 15th St, Augusta, GA 30912 Phone: 574-850-2999 | |
Kristen Beeler, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 1446 Harper St, Augusta, GA 30912 Phone: 706-721-5437 | |
Lorna Evorie Bell, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1120 15th St, Augusta, GA 30912 Phone: 706-721-4951 Fax: 706-721-7941 | |
Dr. William Weston Iii, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 93 Bristlecone Ct., Augusta, GA 30909 Phone: 706-736-3704 | |
Dr. Amanda Chaffin, Pediatrics Medicare: Medicare Enrolled Practice Location: 1120 15th St, Augusta, GA 30912 Phone: 706-721-9442 | |
Aaron W Hanna, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1245 Augusta West Pkwy, Augusta, GA 30909 Phone: 706-868-0389 Fax: 706-651-0729 |